JPRN-UMIN000051667已完成Unknown
Metreleptin for Subcutaneous Injection Post-Marketing Surveillance - Metreleptin for Subcutaneous Injection Post-Marketing Surveillance
Pharmacovigilance Department Shionogi & Co., Ltd.0 个研究点目标入组 48 人开始时间: 2023年7月31日最近更新:
适应症
试验速览
- 阶段
- Unknown
- 状态
- 已完成
- 发起方
- 入组人数
- 48
研究概览
简要总结
Of 48 patients in the safety analysis set, 15 patients (31.25%) experienced an ADR. Of 15 patients in the effectiveness analysis set, the mean value of HbA1c at the final evaluation (n=12) was 6.03%, the rate of change -14.5%, and the mean value of blood triglycerides at the final evaluation (n=15) was 269.3 mg/dL, a rate of change -6.7%.
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- ot applicable 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
已完成
不适用
Special Drug Use-Results Survey for ACTAIR Sublingual Tablets (Long-term Use)Allergic rhinitis due to house dust mitesJPRN-UMIN000042840Shionogi & Co., Ltd.545
已完成
不适用
Prospective observational study on efficacy and safety of PEGASYS for the treatment of patients with HBeAg positive or HBeAg negative chronic active hepatitis BJPRN-UMIN000008045Chugai Pharmaceutical Co., Ltd.536
已完成
不适用
PERJETA® IV Infusion Drug use surveillanceBreast CancerJPRN-UMIN000017699Chugai Pharmaceutical Co., Ltd.261
已完成
不适用
A clinical study to evaluate the feasibility and dose delivery accuracy of Volumetric-modulated Dynamic WaveArc therapyProstate cancer, brain tumor (skull-based tumor)JPRN-UMIN000023870Kyoto University15
已完成
1 期
Topically Applied AMTX-100 CF for Adult Patients With Mild to Moderate Atopic DermatitisAtopic DermatitisNCT04313400Amytrx Therapeutics, Inc.91